These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17638121)

  • 1. Utilities and disutilities for type 2 diabetes treatment-related attributes.
    Matza LS; Boye KS; Yurgin N; Brewster-Jordan J; Mannix S; Shorr JM; Barber BL
    Qual Life Res; 2007 Sep; 16(7):1251-65. PubMed ID: 17638121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.
    Boye KS; Matza LS; Walter KN; Van Brunt K; Palsgrove AC; Tynan A
    Eur J Health Econ; 2011 Jun; 12(3):219-30. PubMed ID: 20224930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change.
    Matza LS; Yurgin N; Boye KS; Malley K; Shorr JM
    Curr Med Res Opin; 2007 Sep; 23(9):2051-62. PubMed ID: 17651535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilities for Type 2 Diabetes Treatment-Related Attributes in a South Korean and Taiwanese Population.
    Rajan N; Boye KS; Gibbs M; Lee YJ; Davey P; Ball M; Babineaux SM
    Value Health Reg Issues; 2016 May; 9():67-71. PubMed ID: 27881263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Davies EW; Paczkowski R
    BMC Health Serv Res; 2017 Nov; 17(1):774. PubMed ID: 29178918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilities for treatment-related adverse events in type 2 diabetes.
    Shingler S; Fordham B; Evans M; Schroeder M; Thompson G; Dewilde S; Lloyd AJ
    J Med Econ; 2015 Jan; 18(1):45-55. PubMed ID: 25266815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.
    Noel CW; Lee DJ; Kong Q; Xu W; Simpson C; Brown D; Gilbert RW; Gullane PJ; Irish JC; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
    JAMA Otolaryngol Head Neck Surg; 2015 Aug; 141(8):696-703. PubMed ID: 26204439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of two generic patient-reported outcome measures in patients with type 2 diabetes.
    Matza LS; Boye KS; Yurgin N
    Health Qual Life Outcomes; 2007 Jul; 5():47. PubMed ID: 17672906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes.
    Xie X; Guo J; Bremner KE; Wang M; Shah BR; Volodin A
    J Comp Eff Res; 2021 Sep; 10(13):961-974. PubMed ID: 34287017
    [No Abstract]   [Full Text] [Related]  

  • 11. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
    Mühlbacher A; Bethge S
    Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A valuation of infusion therapy to preserve islet function in type 1 diabetes.
    Lloyd A; Swinburn P; Boye KS; Curtis B; Sarpong E; Goldsmith K; Bode B; Aronoff S
    Value Health; 2010 Aug; 13(5):636-42. PubMed ID: 20712603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index.
    Sundaram M; Smith MJ; Revicki DA; Miller LA; Madhavan S; Hobbs G
    Pharmacoeconomics; 2010; 28(3):201-16. PubMed ID: 20151725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health state utilities associated with attributes of treatments for hepatitis C.
    Matza LS; Sapra SJ; Dillon JF; Kalsekar A; Davies EW; Devine MK; Jordan JB; Landrian AS; Feeny DH
    Eur J Health Econ; 2015 Dec; 16(9):1005-18. PubMed ID: 25481796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom.
    Levy AR; Christensen TL; Johnson JA
    Health Qual Life Outcomes; 2008 Sep; 6():73. PubMed ID: 18823555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications.
    Yfantopoulos J; Chantzaras A
    Eur J Health Econ; 2020 Jul; 21(5):729-743. PubMed ID: 32128637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health state utilities in gastroesophageal reflux disease patients with heartburn: a study in Germany and Sweden.
    Kartman B; Gatz G; Johannesson M
    Med Decis Making; 2004; 24(1):40-52. PubMed ID: 15005953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey.
    Harris S; Mamdani M; Galbo-Jørgensen CB; Bøgelund M; Gundgaard J; Groleau D
    Can J Diabetes; 2014 Feb; 38(1):45-52. PubMed ID: 24485213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical trial to evaluate the measurement properties of 2 direct preference instruments administered with and without hypothetical marker states.
    Schünemann HJ; Griffith L; Stubbing D; Goldstein R; Guyatt GH
    Med Decis Making; 2003; 23(2):140-9. PubMed ID: 12693876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region.
    Sheu WH; Ji LN; Nitiyanant W; Baik SH; Yin D; Mavros P; Chan SP
    Diabetes Res Clin Pract; 2012 May; 96(2):141-8. PubMed ID: 22265956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.